FOLH1 and prostate carcinoma: 68Ga-PSMA PET/CT has an important role in assessment of prostate cancer patients with biochemical recurrence [6, 26–31] and is evolving in staging high- and intermediate risk disease prior to surgery or radiotherapy [28, 32, 33].